Rufinamide add-on therapy for refractory epilepsy by Panebianco, Mariangela et al.
Cochrane Database of Systematic Reviews
Rufinamide add-on therapy for refractory epilepsy (Review)
Panebianco M, Prabhakar H, Marson AG
Panebianco M, Prabhakar H, Marson AG.
Rufinamide add-on therapy for refractory epilepsy.
Cochrane Database of Systematic Reviews 2018, Issue 4. Art. No.: CD011772.
DOI: 10.1002/14651858.CD011772.pub2.
www.cochranelibrary.com
Rufinamide add-on therapy for refractory epilepsy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
T A B L E O F C O N T E N T S
1HEADER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1ABSTRACT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2PLAIN LANGUAGE SUMMARY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . . . . . . . . . . . . . . . . . . .
7BACKGROUND . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
7OBJECTIVES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
7METHODS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
10RESULTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Figure 1. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11
Figure 2. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13
Figure 3. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
Figure 4. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15
Figure 5. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15
Figure 6. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17
18DISCUSSION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
19AUTHORS’ CONCLUSIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
19ACKNOWLEDGEMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
20REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
23CHARACTERISTICS OF STUDIES . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
37DATA AND ANALYSES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Analysis 1.1. Comparison 1 Rufinamide versus placebo, Outcome 1 ≥ 50% reduction in seizure frequency. . . . . 37
Analysis 1.2. Comparison 1 Rufinamide versus placebo, Outcome 2 Seizure freedom. . . . . . . . . . . . 38
Analysis 1.3. Comparison 1 Rufinamide versus placebo, Outcome 3 Treatment withdrawal. . . . . . . . . . 39
Analysis 1.4. Comparison 1 Rufinamide versus placebo, Outcome 4 Adverse effects. . . . . . . . . . . . . 40
41APPENDICES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
42CONTRIBUTIONS OF AUTHORS . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
42DECLARATIONS OF INTEREST . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
42SOURCES OF SUPPORT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
43DIFFERENCES BETWEEN PROTOCOL AND REVIEW . . . . . . . . . . . . . . . . . . . . .
43INDEX TERMS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
iRufinamide add-on therapy for refractory epilepsy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
[Intervention Review]
Rufinamide add-on therapy for refractory epilepsy
Mariangela Panebianco1 , Hemanshu Prabhakar2, Anthony G Marson1
1Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.
2Department of Neuroanaesthesiology and Critical Care, All India Institute of Medical Sciences, New Delhi, India
Contact address: Mariangela Panebianco, Department of Molecular and Clinical Pharmacology, Institute of Translational
Medicine, University of Liverpool, Clinical Sciences Centre for Research and Education, Lower Lane, Liverpool, L9 7LJ, UK.
m.panebianco@liverpool.ac.uk, dott_mariangela@hotmail.com.
Editorial group: Cochrane Epilepsy Group.
Publication status and date: New, published in Issue 4, 2018.
Citation: PanebiancoM, Prabhakar H,Marson AG. Rufinamide add-on therapy for refractory epilepsy.Cochrane Database of Systematic
Reviews 2018, Issue 4. Art. No.: CD011772. DOI: 10.1002/14651858.CD011772.pub2.
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A B S T R A C T
Background
Epilepsy is a central nervous system disorder (neurological disorder). Epileptic seizures are the result of excessive and abnormal cortical
nerve cell electrical activity in the brain. Despite the development of more than 10 new antiepileptic drugs (AEDs) since the early 2000s,
approximately a third of people with epilepsy remain resistant to pharmacotherapy, often requiring treatment with a combination
of AEDs. In this review, we summarised the current evidence regarding rufinamide, a novel anticonvulsant medication, which, as a
triazole derivative, is structurally unrelated to any other currently used anticonvulsant medication, when used as an add-on treatment
for refractory epilepsy. In January 2009, rufinamide was approved by the US Food and Drug Administration for treatment of children
four years of age and older with Lennox-Gastaut syndrome. It is also approved as an add-on treatment for adults and adolescents with
focal seizures.
Objectives
To evaluate the efficacy and tolerability of rufinamide when used as an add-on treatment in people with refractory epilepsy.
Search methods
On 2 October 2017, we searched the Cochrane Epilepsy Group Specialized Register, the Cochrane Central Register of Controlled
Trials (CENTRAL) via the Cochrane Register of Studies Online (CRSO),MEDLINE (Ovid, 1946), ClinicalTrials.gov and the WHO
International Clinical Trials Registry Platform (ICTRP). We imposed no language restrictions. We also contacted the manufacturers
of rufinamide and authors in the field to identify any relevant unpublished studies.
Selection criteria
Randomised, double-blind, placebo-controlled, add-on trials of rufinamide, recruiting people (of any age or gender) with refractory
epilepsy.
Data collection and analysis
Two review authors independently selected trials for inclusion and extracted the relevant data. We assessed the following outcomes: 50%
or greater reduction in seizure frequency (primary outcomes); seizure freedom; treatment withdrawal; and adverse effects (secondary
outcomes). Primary analyses were intention-to-treat (ITT) and we presented summary risk ratios (RR) with 95% confidence intervals
(CI). We evaluated dose response in regression models. We carried out a risk of bias assessment for each included study using the
Cochrane ’Risk of bias’ tool and assessed the overall quality of evidence using the GRADE approach, which we presented in a ’Summary
of findings’ table.
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Main results
The review included six trials, representing 1759 participants. Four trials (1563 participants) included people with uncontrolled focal
seizures. Two trials (196 participants) included established Lennox-Gastaut syndrome. Overall, the age of the adults ranged from 18 to
80 years and the age of the infants ranged from four to 16 years. Baseline phase ranged from 28 to 56 days and double-blind phases from
84 to 96 days. Five of the six included trials described adequate methods of concealment of randomisation and only three described
adequate blinding. All analyses were by ITT. Overall, five studies were at low risk of bias, and one had unclear risk of bias due to lack
of reported information around study design. All trials were sponsored by the manufacturer of rufinamide, and therefore, were at high
risk of funding bias.
The overall RR for 50% or greater reduction in seizure frequency was 1.79 (95% CI 1.44 to 2.22; 6 RCTs; moderate-quality evidence)
indicating that rufinamide (plus conventional AED) was significantly more effective than placebo (plus conventional AED) in reducing
seizure frequency by at least 50%, when added to conventionally used AEDs in people with refractory focal epilepsy. The overall RR for
treatment withdrawal (for any reason and due to AED) was 1.83 (95% CI 1.45 to 2.31; 6 RCTs; moderate-quality evidence) showing
that rufinamide was significantly more likely to be withdrawn than placebo. In respect of adverse effects, most were significantly more
likely to occur in the rufinamide-treated group. The adverse events significantly associated with rufinamide were: headache, dizziness,
somnolence, vomiting, nausea, fatigue and diplopia. The RRs of these adverse effects were: headache 1.36 (95% Cl 1.08 to 1.69; 3
RCTs; high-quality evidence); dizziness 2.52 (95% Cl 1.90 to 3.34; 3 RCTs; moderate-quality evidence); somnolence 1.94 (95% Cl
1.44 to 2.61; 6 RCTs; moderate-quality evidence); vomiting 2.95 (95% Cl 1.80 to 4.82; 4 RCTs; low-quality evidence); nausea 1.87
(95% Cl 1.33 to 2.64; 3 RCTs; moderate-quality evidence); fatigue 1.46 (95% Cl 1.08 to 1.97; 3 RCTs; moderate-quality evidence);
and diplopia 4.60 (95% Cl 2.53 to 8.38; 3 RCTs; low-quality evidence). There was no important heterogeneity between studies for
any of the outcomes. Overall, we assessed the evidence as moderate to low quality, due to potential risk of bias from some studies
contributing to the analysis and wide CIs.
Authors’ conclusions
In people with drug-resistant focal epilepsy, rufinamide when used as an add-on treatment was effective in reducing seizure frequency.
However, the trials reviewed were of relatively short duration and provided no evidence for the long-term use of rufinamide. In the
short term, rufinamide as an add-on was associated with several adverse events. This review focused on the use of rufinamide in drug-
resistant focal epilepsy and the results cannot be generalised to add-on treatment for generalised epilepsies. Likewise, no inference can
be made about the effects of rufinamide when used as monotherapy.
P L A I N L A N G U A G E S U M M A R Y
Rufinamide add-on therapy for refractory epilepsy
Background
Epilepsy is a central nervous system disorder. Most seizures (fits) can be controlled by a single antiepileptic medicine. Unfortunately,
some people require more than one antiepileptic medicine to control their seizures (called refractory epilepsy or drug-resistant epilepsy),
especially if these originate from one area of the brain (focal epilepsy), instead of being generalised (involve the entirety of the part of the
brain called the cerebral cortex). Rufinamide is a novel anticonvulsant medicine that is structurally unrelated to any other currently used
anticonvulsant medicine. In 2009, rufinamide was approved by the US Food and Drug Administration for the treatment of children
aged four years and older with Lennox-Gastaut syndrome (a childhood epilepsy) and then also approved as an ’add-on’ treatment (given
in addition to the usual anticonvulsant medicine) for adults and adolescents with focal seizures.
Aim of the review
This review aimed to evaluate the effectiveness and side effects of rufinamide when used as an add-on treatment for people with drug-
resistant epilepsy.
Results
We found six clinical trials that included in analysis 1759 people with focal epilepsy. These trials were all randomised controlled trials
(clinical studies where people were randomly put into one of two or more treatment groups) that compared the antiepileptic drug
rufinamide (at doses between 200 mg per day and 3200 mg per day) plus a conventional antiepileptic medicine to a placebo (pretend
tablet) plus a conventional epileptic medicine for up to 96 days.
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The review found that rufinamide, used in combination with other antiepileptic drugs in people who had drug-resistant focal epilepsy
decreased the frequency of seizures further. The review also showed that rufinamide seemed to be associated with more side effects such
as dizziness, tiredness, headache, double vision, nausea and vomiting compared to placebo but more information is needed about some
of these events.
The evidence is current to October 2017.
Quality of the evidence
We assessed the trials with regards to risk of bias and quality. Overall, five studies had low risk of bias, and one study had unclear risk of
bias due to lack of reported information around study design. All studies were conducted by the pharmaceutical industry. We rated the
quality of the evidence as moderate to low as some data were not reported and some information about the trials was unclear. Further
trials are needed to assess the long-term effects of rufinamide, and to compare it with other add-on drugs. Furthermore, future research
should consider rufinamide as add-on treatment for generalised epilepsies and as a single treatment in focal and generalised epilepsy.
3Rufinamide add-on therapy for refractory epilepsy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Rufinamide versus placebo for drug- resistant focal epilepsy
Patient or population: people with drug-resistant focal epilepsy
Settings: outpat ients
Intervention: ruf inamide
Comparison: placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo Rufinamide
50% or greater reduc-
tion in seizure fre-
quency - ITT analysis
Study population RR 1.79
(1.44 to 2.22)
1759
(6 studies)
⊕⊕⊕©
Moderate1
RR > 1 indicates out-
come is more likely in
ruf inamide group.143 per 1000 256 per 1000
(206 to 317)
Treatment withdrawal Study population RR 1.83
(1.45 to 2.31)
1759
(6 studies)
⊕⊕⊕©
Moderate1
RR > 1 indicates out-
come is more likely in
ruf inamide group.112 per 1000 205 per 1000
(162 to 259)
Adverse effects: dizzi-
ness
Study population RR 2.52
(1.90 to 3.34)
1295
(3 studies)
⊕⊕⊕©
Moderate1
RR > 1 indicates out-
come is more likely in
ruf inamide group.108 per 1000 272 per 1000
(205 to 361)
Adverse effects: fa-
tigue
Study population RR 1.46
(1.08 to 1.97)
1295
(3 studies)
⊕⊕⊕©
Moderate1
RR > 1 indicates out-
come is more likely in
ruf inamide group.112 per 1000 164 per 1000
(121 to 221)
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Adverse effects:
headache
Study population RR 1.36
(1.08 to 1.69)
1228
(3 studies)
⊕⊕⊕©
Moderate1
RR > 1 indicates out-
come is more likely in
ruf inamide group.196 per 1000 267 per 1000
(212 to 331)
Adverse effects: som-
nolence
Study population RR 1.94
(1.44 to 2.61)
1759
(6 studies)
⊕⊕⊕©
Moderate1
RR > 1 indicates out-
come is more likely in
ruf inamide group.82 per 1000 159 per 1000
(118 to 214)
Adverse effects: nau-
sea
Study population RR 1.87
(1.33 to 2.64)
1295
(3 studies)
⊕⊕⊕©
Moderate1
RR > 1 indicates out-
come is more likely in
ruf inamide group.82 per 1000 153 per 1000
(109 to 216)
Adverse effects: vom-
iting
Study population RR 2.95
(1.80 to 4.82)
777
(4 studies)
⊕⊕©©
Low2
RR > 1 indicates out-
come is more likely in
ruf inamide group.49 per 1000 145 per 1000
(88 to 236)
Adverse effects:
diplopia
Study population RR 4.60
(2.53 to 8.38)
1295
(3 studies)
⊕⊕©©
Low2
RR > 1 indicates out-
come is more likely in
ruf inamide group.24 per 1000 110 per 1000
(61 to 201)
* The basis for the assumed risk4(e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: conf idence interval; ITT: intent ion to treat; RR: risk rat io.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1. Downgraded once due to risk of bias: unclear methodological information provided for some included studies and all
included studies pharmaceut ical sponsored.
2. Downgraded once due to imprecision: Wide conf idence intervals.
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3.Assumed risk is calculated as the event rate in the control group per 1000 people (number of events divided by the number
of part icipants receiving control treatment).
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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B A C K G R O U N D
Description of the condition
Epilepsy is a central nervous system disorder (neurological disor-
der). The definition of epilepsy, as recommended by the Interna-
tional League Against Epilepsy (ILAE) Commission on Epidemi-
ology, is as follows: “two or more unprovoked seizures occurring
more than 24 hr apart” (ILAE Commission on Epidemiology and
Prognosis 1993). Epileptic seizures are the result of excessive and
abnormal cortical nerve cell electrical activity in the brain.
Epilepsy imposes a significant clinical, epidemiological and eco-
nomic burden on societies worldwide. Despite the development
of more than 10 new antiepileptic drugs (AEDs) since the early
2000s, approximately a third of people with epilepsy remain resis-
tant to pharmacotherapy, often requiring treatment with a combi-
nation of AEDs. The proportion of people with refractory seizures
varies in the literature between 6% and 35% (Granata 2009).
Therefore, the development of effective new therapies for the treat-
ment of refractory seizures is of considerable importance. Since
the late 1990s, the introduction of several new drugs, which of-
ten are better tolerated and more manageable than the older ones,
has certainly improved our ability to treat people with epilepsy
(Panebianco 2015a). Studies have reported that 12% to 17%
of treatment-resistant people become seizure-free with the addi-
tion of a previously untried, in most cases new-generation, AED
(Granata 2009).
Description of the intervention
Rufinamide (1-(2,6-difluoro-phenyl) methyl-1 hydro-1,2,3-tria-
zole-4 carboxamide) is a novel anticonvulsant medication, which,
as a triazole derivative, is structurally unrelated to any other cur-
rently used anticonvulsant medications. It was granted orphan
drug status for the adjunctive treatment of people with Lennox-
Gastaut syndrome (LGS) in the US in 2004, and was released for
use in Europe in 2007. In January 2009, rufinamide was approved
by the US Food and Drug Administration for treatment of chil-
dren aged four years and older with LGS (Coppola 2011; Hsieh
2013). It is also approved as adjunctive treatment for adults and
adolescents with focal seizures. There has been renewed interest in
the development of newer AEDs, as several of the standard ones
are not always effective and are associated with adverse effects.
In the first instance, new AEDs are tested in RCTs as an add-
on treatment for people with drug-resistant focal epilepsy. Once a
therapeutic effect is reported by these trials, new AEDs tend to be
licenced for add-on use before monotherapy trials have compared
new AEDs versus standard treatments. Placebo-controlled studies
of rufinamide that have provided efficacy data include trials in-
volving people with LGS, people with adult focal-onset seizures
(for both monotherapy and adjunctive therapy), children with fo-
cal-onset seizures in need of adjunctive therapy and people with
refractory generalised tonic-clonic seizures (Biton 2005).
How the intervention might work
The precise mechanisms by which rufinamide exerts its antiepilep-
tic effects are unknown. In vitro studies suggest that a principal
mechanism of action is themodulation of activity in sodium chan-
nels, particularly prolongationof the inactive state. In cultured cor-
tical neurons from immature rats, rufinamide significantly slowed
sodium channel recovery from inactivation after a prolonged pre-
pulse and limited sustained repetitive firing of sodium-dependent
action potentials. Rufinamide has no effect on benzodiazepine or
gamma-aminobutyric acid (GABA) receptors, or on adenosine up-
take; it also has no significant interactions with glutamate, adren-
ergic tryptophan, histamine or muscarinic cholinergic receptors
(Wheless 2010). The overall tolerability of rufinamide is good.
Most adverse events in clinical trials were mild to moderate, and
they were often transient in nature, largely occurring during the
titration phase (Wheless 2009).
Why it is important to do this review
The purpose of this review was to report evidence from RCTs on
the efficacy and tolerability of rufinamide used as add-on treat-
ment for people with drug-resistant epilepsy. This review aimed
to address these issues and inform clinical practice and future re-
search.
O B J E C T I V E S
To evaluate the efficacy and tolerability of rufinamide when used
as an add-on treatment in people with refractory epilepsy.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Studies were required to meet all the following criteria:
1. RCTs;
2. double- or single-blinded trials;
3. placebo-controlled, or with an alternative AED or range of
rufinamide doses used as controls;
4. parallel-group or cross-over studies;
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5. minimum treatment period of eight weeks.
Types of participants
We considered participants who satisfied both of the following
criteria:
1. any age; and
2. diagnosis of drug-resistant epilepsy (i.e. experiencing simple
focal, complex focal or secondarily generalised tonic-clonic
seizures).
Types of interventions
1. Active treatment group, wherein participants received
treatment with rufinamide in addition to conventional AED
treatment.
2. Control group(s), wherein participants received a matched
placebo/different dose/alternative AED in addition to
conventional AED treatment.
Types of outcome measures
Primary outcomes
1. Fifty percent or greater reduction in seizure frequency:
proportion of people with a 50% or greater reduction in seizure
frequency during the treatment period compared with the pre-
randomisation baseline period.
Secondary outcomes
1. Seizure freedom: proportion of people with complete
cessation of seizures during the treatment period.
2. Treatment withdrawal: proportion of people with
treatment withdrawn during the course of the treatment period
as a measure of ’global effectiveness.’ Treatment is likely to be
withdrawn due to adverse effects, lack of efficacy or a
combination of both, and this is an outcome to which
participants make a direct contribution. In trials of shorter
duration, it is likely that adverse effects will be the most common
reason for withdrawal.
3. Adverse effects: proportion of people who experienced the
following adverse effects:
i) dizziness;
ii) fatigue;
iii) headache;
iv) somnolence;
v) nausea;
vi) vomiting;
vii) psychiatric adverse effects (anxiety, depression, panic
attack, irritability, trouble sleeping, mood or behaviour changes);
viii) loss of appetite;
ix) diplopia;
x) fever;
xi) loss of co-ordination;
xii) difficulty walking;
xiii) allergic reaction.
4. Quality of life (QoL): difference between intervention and
control group(s) means for QoL measures used in individual
studies.
5. Cognition: difference between intervention and control
group(s) means for cognitive assessments used in individual
studies.
6. Mood: difference between intervention and control
group(s) means for mood assessments used in individual studies.
Search methods for identification of studies
Electronic searches
We searched the following databases.
1. Cochrane Epilepsy Group Specialized Register (2 October
2017), using the search strategy set out in Appendix 1.
2. Cochrane Central Register of Controlled Trials
(CENTRAL) via the Cochrane Register of Studies Online
(CRSO, 2 October 2017), using the search strategy set out in
Appendix 2.
3. MEDLINE (Ovid, 1946 to 2 October 2017), using the
search strategy set out in Appendix 3.
4. ClinicalTrials.gov (2 October 2017), using the search terms:
rufinamide AND epilepsy.
5. WHO International Clinical Trials Registry Platform
(ICTRP, 2 October 2017), using the search terms: rufinamide
AND epilepsy.
There were no language restrictions.
Searching other resources
We checked reference lists of retrieved studies for additional re-
ports of relevant studies. We contacted lead study authors for rel-
evant unpublished material. We identified duplicate studies by
screening reports according to title, study author names, location
and medical institute. We omitted duplicate studies.
We identified any grey literature studies published from 2012 to
2017 by searching:
1. Zetoc database;
2. Institute for Scientific Information (ISI) proceedings;
3. International Bureau for Epilepsy (IBE) congress
proceedings database;
4. ILAE congress proceedings database; and
5. abstract books of symposia and congresses, meeting
abstracts and research reports.
8Rufinamide add-on therapy for refractory epilepsy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Data collection and analysis
Selection of studies
Two review authors (MP and HP) independently assessed all ci-
tations generated by the searches for inclusion. We resolved any
disagreements by discussion with a third review author (AGM).
Two review authors (MP and HP) independently extracted data
and assessed risk of bias; we resolved disagreements by discussion
with a third review author (AGM).
Data extraction and management
Two review authors (MP and HP) independently extracted data
from each included study. We cross-checked the data extracted.
Review authors discussed disagreements (bringing in a third review
author (AG) to arbitrate if need be), documented decisions and,
if necessary, contacted trialists for clarification.
We extracted the following information for each trial using a pre-
standardised data extraction form:
Methodological and trial design
1. Methods of randomisation and allocation concealment.
2. Method of blinding.
3. Whether any participants were excluded from reported
analyses.
4. Length of baseline period.
5. Length of treatment period.
6. Dose(s) of rufinamide tested.
Participant/demographic information
1. Total number of participants allocated to each treatment
group.
2. Age/sex.
3. Number with focal/generalised epilepsy.
4. Seizure types.
5. Seizure frequency during the baseline period.
6. Number of background drugs.
Outcomes
1. Number of people experiencing each outcome (see Types of
outcome measures) per randomly assigned group.
2. Contacted authors of trials to ask for missing information.
We collated multiple reports of the same study, so that each study
rather than each report was the unit of interest in the review. We
collected characteristics of the included studies in sufficient detail
to populate a table of ’Characteristics of included studies’.
Assessment of risk of bias in included studies
Two review authors (MP and HP) independently assessed the risk
of bias of each included study.We cross-checked risk of bias assess-
ments and discussed and resolved any disagreements. We utilised
theCochrane ’Risk of bias’ tool as described in theCochrane Hand-
book for Systematic Reviews of Interventions (Higgins 2011). We
rated included studies as having low, high and unclear risk of bias
for six domains applicable to RCTs: randomisation method, allo-
cation concealment, blinding methods, incomplete outcome data,
selective outcome reporting and other sources of bias. We made
an overall summary judgement of risk of bias for each study per
outcome, followed by an overall judgement per outcome across
studies. We incorporated risk of bias judgements into the analysis
using sensitivity analysis, in that a secondary analysis of the data
included only studies rated as having low risk of bias. We pre-
sented all results in the ’Results’ section of the review. We created
Summary of findings for the main comparison for outcomes and
graded each outcome accordingly using the GRADE approach
(Guyatt 2008).
Measures of treatment effect
We presented the primary outcome of seizure reduction as risk
ratios (RRs) and 95% confidence intervals (CIs). We presented
secondary outcomes, including seizure freedom, treatment with-
drawal and adverse effects, as RRs and 95% CIs.
Dealing with missing data
We sought missing data from the study authors. We carried out
intention-to-treat (ITT), best-case and worst-case analyses on the
primary outcome for missing data (see Data synthesis). We in-
cluded all analyses in the main report.
Assessment of heterogeneity
We assessed clinical heterogeneity by comparing the distribution
of important individual participant factors among trials (e.g. age,
seizure type, duration of epilepsy, number of AEDs taken at the
time of randomisation) and trial factors (e.g. randomisation con-
cealment, blinding, losses to follow-up). We examined statistical
heterogeneity using a Chi2 test and the I2 statistic for heterogene-
ity and, provided no significant heterogeneity was present (P >
0.10), we employed a fixed-effect model. In the event that there
was heterogeneity, we performed a random-effects model analysis
using the inverse variance method.
Assessment of reporting biases
Protocol versus full study
We requested all protocols from study authors to enable a com-
parison of outcomes of interest. In the event that a protocol was
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not available, we investigated outcome reporting bias using the
ORBIT matrix system (Kirkham 2010).
Funnel plot
Reporting biases arise when dissemination of research findings is
influenced by the nature and direction of results (Higgins 2011;
Sterne 2000). We used funnel plots in investigating reporting bi-
ases with awareness that they have limited power to detect small-
study effects. We did not use funnel plots for outcomes when 10
or fewer studies were included, or when all studies were of similar
size. In other cases, when funnel plots were possible, we sought
statistical advice on their interpretation.
Data synthesis
We employed a fixed-effect model meta-analyses to synthesise the
data. We expected to carry out the following comparisons:
1. Intervention group versus controls on 50% or greater
reduction in seizure frequency.
2. Intervention group versus controls on seizure freedom.
3. Intervention group versus controls on treatment
withdrawal.
4. Intervention group versus controls on individual adverse
effects.
5. Intervention group versus controls on QoL.
We stratified each comparison by type of control group, that is,
placebo or active control, and types of study characteristics, to
ensure the appropriate combination of study data. Our preferred
estimator was theMantel-Haenszel RR. For the outcomes 50% or
greater reduction in seizure frequency, seizure freedom and treat-
ment withdrawal, we used 95%CIs. For individual adverse effects,
we used 99% CIs to allow for multiple testing. Our analyses in-
cluded all participants in the treatment groups to which they were
allocated. For the efficacy outcome (50% or greater reduction in
seizure frequency), we undertook three analyses.
1. Primary (ITT analysis): participants not completing follow-
up or with inadequate seizure data were assumed non-responders.
To test the effect of this assumption, we undertook the following
sensitivity analyses. We performed ITT analysis when this was
reported by the included studies.
a) Worst-case analysis: participants not completing follow-up or
with inadequate seizure data were assumed to be non-responders
in the intervention group, and responders in the placebo group.
b) Best-case analysis: participants not completing follow-up or
with inadequate seizure data were assumed to be responders in the
intervention group, and non-responders in the placebo group.
We investigated effects of rufinamide at ranging between doses
between 200 mg per day and 3200 mg per day. When trials com-
pared more than one dose, doses were pooled and a comparison
of rufinamide versus control was made.
We summarised selected models by expected response rates and
expected differences in response rates by dose level compared with
placebo.
Subgroup analysis and investigation of heterogeneity
We analysed different adverse effects separately. We aimed to as-
sess clinical heterogeneity by comparing the distribution of impor-
tant individual participant factors among trials (e.g. age, seizure
type, duration of epilepsy, number of AEDs taken at the time of
randomisation) and trial factors (e.g. randomisation concealment,
blinding, losses to follow-up).
Sensitivity analysis
We intended to carry out a sensitivity analysis if we found pecu-
liarities between study quality, characteristics of participants, in-
terventions and outcomes (assessment of risk of bias in included
studies). We also reported the analysis for all studies and then
compared it with an analysis including only studies at low risk of
bias.
R E S U L T S
Description of studies
Results of the search
The search revealed 137 records identified. After duplicates were
removed, 95 records remained and we screened all for inclusion in
the review. We excluded 58 due to irrelevance leaving 37 full-text
articles to be assessed for eligibility. Following this, we excluded 13
studies (see Figure 1 and Characteristics of excluded studies table
for reasons of exclusion). A total of 24 studies were included in the
review, six of which were included in meta-analyses and 18 were
linked to included studies.We identified three conference abstracts
and contacted the authors of these studies for more information,
providing their contact details were available (see Figure 1 and
Characteristics of included studies table).
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Figure 1. Study flow diagram.
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Included studies
Overall, two RCTs compared rufinamide to a placebo in infants
and adults aged four to 63 years (Glauser 2008; Ohtsuka 2014),
two RCTs that examined rufinamide versus placebo in adolescents
and adults aged 12 to 80 years (Biton 2011; Elger 2010), one study
that examined rufinamide versus placebo in children aged four
to 16 years (Glauser 2005), and one trial comparing rufinamide
versus placebo in adults aged over 16 years (Brodie 2009). All
the trials were sponsored by Eisai pharmaceutical company and
one of these conducted by Novartis (Glauser 2008). In all trials,
participants were eligible to take part in the double-blind period
of the trials if they had uncontrolled focal seizures with or without
secondary generalisation (Biton 2011; Brodie 2009; Elger 2010;
Glauser 2005), or with established LGS (Glauser 2008; Ohtsuka
2014), and were currently taking one to two or up to three AEDs.
See Characteristics of included studies table.
One parallel, multi-centre trial had a pre-randomisation period of
56 days and a treatment period of 96 days (12-day titration period
followed by 84-day maintenance phase), randomising 176 partici-
pants to rufinamide and 181 to placebo (Biton 2011). Participants
were aged 12 to 80 years with inadequately controlled focal-onset
seizures with or without secondary generalisation.
One multi-centre, parallel trial enrolled 313 adults aged over 16
years with refractory focal seizures (Brodie 2009). It randomised
156 participants to rufinamide 3200 mg and 157 to placebo. This
trial had an eight-week baseline phase and 13-week treatment
phase (two-week titration period followed by 11-week mainte-
nance phase).
Onemulti-centre parallel trial enrolled 647 adolescents and adults
aged 15 to 65 years with refractory focal seizures with or without
secondary generalisation. It randomised them to one of five treat-
ment arms: rufinamide 200 mg (127 participants), rufinamide
400 mg (125 participants), rufinamide 800 mg (129 participants),
rufinamide 1600 mg (133 participants) or placebo (133 partici-
pants) (Elger 2010). The baseline phase was 12 weeks followed by
a treatment phase of 12 weeks.
One multi-centre, parallel study included 268 children aged four
to 16 years with refractory focal seizures. It had two treatment
arms: rufinamide 45 mg/kg (135 participants) or placebo (133
participants) (Glauser 2005). The baseline period was 56 days and
the treatment period was 91 days (14-day titration phase followed
by 77-day maintenance phase).
One parallel study randomised 139 participants (but one of these
did not receivedmedication) aged four to 30 yearswith diagnosis of
LGS (Glauser 2008). It consisted of two treatment arms including
rufinamide 45 mg/kg (dose by bodyweight: 1000 mg, 1800 mg,
2400 mg and 3200 mg) per day (74 participants) or placebo (64
participants). This trial had a baseline phase of 28 days and a
double-blind treatment phase of 84 days.
One multi-centre, parallel trial in Japan included 59 participants
(but one participant in the rufinamide group was excluded from
the efficacy analysis due to inappropriate diagnosis) aged four to
30 years with LGS (Ohtsuka 2014). It had two treatment arms:
rufinamide 45mg/kg (28 participants) (dose by bodyweight: 1000
mg, 1800 mg, 2400 mg and 3200 mg) or placebo arm (30 partic-
ipants). This trial had a four-week baseline phase, 12-week treat-
ment phase (two-week titration followed by 10-weekmaintenance
phase) and a further phase which was either a follow-up visit or
entry into an open-label extension.
Overall, the six RCTs recruited 1759 participants and between
them tested rufinamide doses of 200 mg, 400 mg, 800 mg, 1000
mg, 1600 mg, 1800 mg, 2400 mg and 3200 mg per day. For fur-
ther information on each trial, see the Characteristics of included
studies table.
Excluded studies
Weexcluded13RCTs for the following reasons: five studies had in-
eligible populations (Biton 2005; Critchley 2005;Madeddu 2013;
Palhagen 2001; Xu 2016), four studies were not RCTs (Benedict
2010; Kim 2012; Kluger 2007; Knupp 2016), two studies had no
rufinamide in add-on (Lesser 2005; Todorov 2005), and one study
was conference proceedings and no data were available (Racine
2000). In addition, we found one ongoing study (Arzimanoglou
2016).
Risk of bias in included studies
See Figure 2 and Figure 3 for a summary of the ’Risk of bias’ in
each included study. We allocated each study an overall rating for
risk of bias. All studies included in the review were individually
rated as either low risk of bias or unclear risk of bias. See below
for specific domain ratings.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Figure 3. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
Allocation
In five trials, we rated the methods by which allocation was con-
cealed at low risk of bias (Biton 2011; Brodie 2009; Elger 2010;
Glauser 2008; Ohtsuka 2014). One trial did not provide informa-
tion and was at unclear risk of bias for this domain (Glauser 2005).
For sequence generation, we rated five studies at low risk of bias
due to the use of a computer-generated randomisation schedule or
random permuted blocks (Biton 2011; Brodie 2009; Elger 2010;
Glauser 2008; Ohtsuka 2014). We rated one study at unclear risk
of bias due to a lack of details on themethods used (Glauser 2005).
Blinding
We rated the blinding of participants and personnel at low risk
of bias in four studies (Biton 2011; Brodie 2009; Glauser 2008;
Ohtsuka 2014); there were no details for remaining two studies
rated at unclear risk of bias (Elger 2010; Glauser 2005). Blinding
of the outcome assessor was difficult to judge due to the lack of
detail in three trials (Elger 2010; Glauser 2005; Glauser 2008),
and therefore we rated these as unclear in terms of bias. We rated
the other three studies at low risk of bias for outcome assessor
(Biton 2011; Brodie 2009; Ohtsuka 2014). In five trials (Biton
2011; Brodie 2009; Elger 2010; Glauser 2005; Ohtsuka 2014)
blinding was achieved by using identical medication within the
rufinamide and placebo groups.
Incomplete outcome data
We rated five studies as low risk of bias for attrition bias due to the
ITT analyses undertaken by the study authors (Biton 2011; Brodie
2009; Elger 2010; Glauser 2008; Ohtsuka 2014). One study was
at unclear risk of bias (Glauser 2005).
Selective reporting
We requested the protocols for all included studies to compare a
priori methods and outcomes to the published report, but these
were unavailable. We rated all included studies at low risk of bias
for this domain as there was no suspicion of selective outcome
reporting bias: all expected outcomes were reported in each of the
publications.
Other potential sources of bias
All the studies were sponsored by Eisai Inc., the manufacturers of
the rufinamide, and therefore, we rated all studies as having a high
risk of funding bias. There was no evidence of further bias in any
of the included studies.
Effects of interventions
See: Summary of findings for themain comparisonRufinamide
versus placebo for drug-resistant focal epilepsy
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See Summary of main results for the main comparison rufinamide
versus placebo for refractory epilepsy.
The data were not heterogeneous and we performed no ’best case’
or ’worst case’ analyses.
Fifty percent or greater reduction in seizure
frequency
Six RCTs (1759 participants) reported 50% or greater or greater
reduction in seizure frequency. A Chi2 test for heterogeneity in
a response to rufinamide showed no significant heterogeneity be-
tween trials (Chi2 = 5.76, degrees of freedom (df ) = 5, P = 0.33).
Those participants allocated rufinamide were significantly more
likely to achieve 50% or greater reduction in seizure frequency
(223/1067 participants with rufinamide versus 99/692 partici-
pants with placebo). Using the fixed-effect model, the overall RR
was 1.79 (95% CI 1.44 to 2.22; Analysis 1.1; Figure 4, moderate
quality evidence).
Figure 4. Rufinamide versus placebo, outcome: 1.1 50% reduction in seizure frequency.
Seizure freedom
Data from only one study (73 participants) reported seizure free-
dom. There was seizure freedom in 6/44 participants with rufi-
namide versus 3/29 participants with placebo; RR 1.32, 95% CI
0.36 to 4.86; Analysis 1.2, moderate quality evidence).
Treatment withdrawal (any reason and due to
adverse effects)
Six RCTs (1759 participants) reported treatment withdrawal. A
Chi2 test for heterogeneity suggested no significant statistical het-
erogeneity between trials (Chi2 = 5.85, df = 5, P = 0.32). Partici-
pants allocated rufinamide were significantly more likely to with-
draw from treatment (247/1067 participants with rufinamide ver-
sus 78/692 participants with placebo). The overall RR for with-
drawal for any reason and due to AED was 1.83 (95% CI 1.45 to
2.31; Analysis 1.3; Figure 5, moderate quality evidence).
Figure 5. Forest plot of comparison: 1 Rufinamide versus placebo, outcome: 1.3 Treatment withdrawal.
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Adverse effects
The RRs for more common adverse effects were as follows (no
significant statistical heterogeneity between trials); (Analysis 1.4;
Figure 6).
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Figure 6. Rufinamide versus placebo: 1 Rufinamide versus placebo: 1.4 Adverse effects.
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• Dizziness (three RCTs, 1295 participants) in 181/830
participants with rufinamide versus 50/465 participants with
placebo (RR 2.52, 99% CI 1.90 to 3.34, moderate quality
evidence).
• Fatigue (three RCTs, 1295 participants) in 148/830
participants with rufinamide versus 52/465 participants with
placebo (RR 1.46 99% CI 1.08 to 1.97, moderate quality
evidence).
• Headache (three RCTs, 1228 participants) in 214/805
participants with rufinamide versus 83/423 participants with
placebo (RR 1.36, 99% CI 1.08 to 1.69, moderate quality
evidence).
• Somnolence (six RCTs, 1759 participants) in 144/1067
participants with rufinamide versus 57/692 participants with
placebo (RR 1.94, 99% CI 1.44 to 2.61, moderate quality
evidence).
• Nausea (three RCTs, 1295 participants) in 106/830
participants with rufinamide versus 38/465 participants with
placebo (RR 1.87, 99% CI 1.33 to 2.64, moderate quality
evidence).
• Vomiting (four RCTs, 777 participants) in 59/393
participants with rufinamide versus 19/384 participants with
placebo (RR 2.95, 99% CI 1.80 to 4.82, low quality evidence).
• Diplopia (three RCTs, 1295 participants) in 82/830
participants with rufinamide versus 11/465 participants with
placebo (RR 4.60, 99% CI 2.53 to 8.38, low quality evidence).
Only one RCT reported the remaining adverse effects.
• Psychiatric adverse effects (anxiety, depression, panic attack,
irritability, trouble sleeping, mood or behaviour changes).
• Loss of appetite.
• Fever.
• Loss of co-ordination.
D I S C U S S I O N
Summary of main results
The review included six trials, with 1759 participants included in
the analysis. Four trials (1563 participants) included people with
uncontrolled focal seizures. Two trials (196 participants) included
established LGS. Overall, adults were aged from 18 to 80 years,
and infants were aged from four to 16 years. The baseline phase in
all trials ranged from 28 to 56 days, and the treatment phase from
84 to 96 days. Five of the six included trials described adequate
methods of concealment of randomisation. Three studies reported
effective blinding. All analyses were by ITT. The manufacturer of
rufinamide, Eisai Inc., sponsored all trials, and therefore, we rated
them at high risk of bias. Overall, five studies were at low risk
of bias, and one had unclear risk of bias due to lack of reported
information around study design.
This meta-analysis suggested that rufinamide was more effective
than placebo in reducing seizure frequency by at least 50%, when
used in combination with other AEDs (from one to three) in peo-
ple with refractory focal epilepsy.We were unable to examine dose
effects in the planned subgroup analyses, but the results suggested
increased efficacywith an increased dose. Only one study recruited
children; we have no evidence from this review to indicate whether
rufinamide is more or less effective in infants and children than
in adults. The use of 50% or more reduction in seizure frequency
as a measure of efficacy could be criticised, given that seizure free-
dom would be a more relevant clinical measure. However, only
one study reported data on seizure freedom and, therefore, this
finding must be interpreted with caution.
Results for treatment withdrawal (any reason and due to adverse
effects) showed that rufinamide was significantly more likely to be
withdrawn than placebo. In trials of relatively short duration, such
as those reviewed here, this is likely to represent problems with
tolerability rather than poor seizure control. Most of the adverse
effects were significantly more likely to occur in the rufinamide-
treated group.
This review focused on the use of rufinamide in drug-resistant fo-
cal epilepsy and the results cannot be generalised to add-on treat-
ment for generalised epilepsies. Likewise, no inference canbemade
about the effects of rufinamide when used as monotherapy.
Review findings were not compared with other published evi-
dence, because we found no previous reviews or published infor-
mation on this topic.
Overall completeness and applicability of
evidence
Caution is required when translating the results of clinical trials
into everyday practice, since the participants in trials are a highly
selected population who may be better motivated, and are closely
followed and monitored; participants who are unco-operative and
non-compliant, who are likely to have adverse effects and fewer
benefits, are excluded. The results of this review cannot be extrap-
olated to people with generalised epilepsies, about whom there is
a great paucity of data. The safety of rufinamide during pregnancy
and lactation cannot be ascertained from this review. The duration
of the studies included in this review was insufficient to detect
changes in cognition, social problems or long-term adverse effects.
Rare phenomena such as habituation and tolerance may not be
evident in short-term trials. The economic aspects of rufinamide
therapy also needs to be examined.
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Quality of the evidence
Overall, five studies were at low risk of bias and one at unclear risk
of bias due to lack of reported information around study design.
Only three studies had effective blinding of rufinamide. We rated
all the included studies at low risk of bias for incomplete outcome
data due to the ITT analyses undertaken by the study authors.
We used the GRADE approach to rate the quality of evidence for
each outcome, which is presented in Summary of findings for the
main comparison. For the main outcome of 50% or greater re-
duction in seizure frequency, the quality of evidence was high (all
studies contributed to the analysis). Tolerability outcomes (with-
drawal and adverse effects) were at moderate-to-low quality due to
potential risk of bias from some studies contributing to the anal-
ysis and wide CIs.
Potential biases in the review process
Although we requested all protocols, the time frames in which
the majority of the studies were conducted made retrieval of all
these difficult. This could lead to potential bias through omitted
information to which we did not have access.
All studies were sponsored by Eisai Inc., the manufacturers of
rufinamide, and this could be a potential source of bias.
Agreements and disagreements with other
studies or reviews
We found no reviews or published information on the use of ru-
finamide as add-on therapy for refractory epilepsy.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
In people with drug-resistant focal epilepsy, rufinamide when used
as an add-on treatment was effective in reducing seizure frequency.
However, the trials reviewed were of relatively short duration, the
participants were followed up for three to six months and evidence
regarding some adverse events is limited and imprecise.
Implications for research
Further evaluation of rufinamide is required to assess the following
effects in the long term:
1. effects on seizures (in terms of “seizure freedom” together
with the proportion of people who have certain percentage
reduction in seizure episode, and “seizure-associated mortality”);
2. adverse effects;
3. effects on cognition;
4. effects on quality of life;
5. health economic effects.
Evaluation of the effects of rufinamide in the following scenarios
is also required:
1. rufinamide for generalised epilepsy;
2. more trials to assess rufinamide for children and adolescents;
3. rufinamide compared to other add-on treatments in drug-
resistant focal epilepsy;
4. rufinamide compared with standard antiepileptic drugs
such as:
i) rufinamide as monotherapy in focal epilepsy, and
ii) rufinamide as monotherapy in generalised epilepsy.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Biton 2011
Methods Randomised, double-blind, placebo-controlled, parallel-group multi-centre study
Number of control centres: 65.
Country/location: US and Canada.
2 treatment arms: 1 rufinamide, 1 placebo.
Participants Participants: adolescents and adults (aged 12-80 years) with inadequately controlled
focal-onset seizures
Gender: 46.9% male (rufinamide group 47.7%; placebo group 46.1%)
Mean age (years): 37.3 (rufinamide group 36.4; placebo group 38.1)
Mean weight (kg): 78.2 (rufinamide group 77.4; placebo group 79.0)
Ethnic groups: black 9.3%; white 80.1%, Hispanic 7.6%; other 3.0%
Median number of seizures: 13.3 (rufinamide group 13; placebo group 13.8)
Duration of epilepsy: not reported.
Inclusion criteria: males or females, aged 12-80 years, with focal-onset seizures with
or without secondarily generalised seizures; person’s seizures inadequately controlled on
stable doses of up to 3 concomitantly administered AEDs, with no evidence of AED
treatment non-compliance
Exclusion criteria: known generalised epilepsies or history of status epilepticus or seizure
clusters in the past year, or if they required felbamate, vigabatrin or rescue benzodi-
azepines; moreover, if they had clinically significant medical or psychiatric disease, clin-
ically significant ECG abnormality, or a diagnosis of congenital short QT syndrome,
psychogenic seizures in the previous year, history of drug abuse and/or positive finding
on urinary drug screening, or a history of alcohol abuse in the past 2 years
Diagnostic criteria: established by clinical history, electroencephalography, and CT/MRI
of the brain performed within the last 10 years
Comorbidities: none.
Comedications: ≤ 3 AEDs.
Total people randomised 357: rufinamide group 176; placebo group 181. One partic-
ipant was excluded from the analysis because required laboratory assessments were not
obtained. 61 people withdrew from study: rufinamide group 37; placebo group 24
Interventions Intervention: rufinamide 3200 mg/day
Control: placebo.
2-phase study: 56-day baseline/screening phase; and 96-day treatment phase (12-day
titration period followed by 84-day maintenance phase)
Outcomes Primary outcomes (as stated in publication):
1. % change in total focal seizures frequency per 28 days during maintenance phase
relative to baseline.
Secondary outcomes (as stated in publication):
1. % responders (50% and 75%);
2. adverse effects.
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Biton 2011 (Continued)
Notes Stated aim of study: “This randomized study was conducted to evaluate and confirm
the efficacy and safety (seizure control and adverse effects) of rufinamide as adjunctive
treatment for refractory focal-onset seizures.”
Language of publication: English.
Commercial funding: yes.
Publication status (peer review journal): yes.
Publication status (journal supplement): no.
Publication status (abstract): no.
Funded by Eisai Medical Research.
No conflict of interest.
NCT00334958 is linked to this study.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated schedule using blocks
of 4.
Allocation concealment (selection bias) Low risk Allocated participants to each of the 2 treat-
ment groups in a 1:1 ratio
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participant and clinical staff blinded.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Investigators blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition rates reported. ITT efficacy anal-
ysis employed.
Selective reporting (reporting bias) Low risk Protocol unavailable but appeared all ex-
pected and prespecified outcomes were re-
ported
Other bias High risk Sponsored by Eisai Inc., the manufacturer
of rufinamide.
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Brodie 2009
Methods Randomised, double-blind, placebo-controlled, parallel-group multi-centre study
Number of control centres: 48.
Country/location: 17 centres in US and 31 international centres in Argentina, Chile,
France, UK, Germany, Italy, Russia, Slovakia, South Africa, Spain, Switzerland and
Uruguay
2 treatment arms: 1 rufinamide, 1 placebo.
Participants Participants: adolescents and adults ≥ 16 years with refractory focal seizures
Gender: 44.4% male (rufinamide group 40.4%; placebo group 48.4%)
Mean age (years): 36.8 (rufinamide group 35.8; placebo group 37.9)
Mean weight (kg): 74.2 (rufinamide group 73.1; placebo group 75.3)
Ethnic groups: black 3.8%; white/Caucasian 85.6%; other 10.5%
Median number of focal seizures: 8.3.
Duration of epilepsy: not reported.
Inclusion criteria: aged ≥ 16 years, weighed ≥ 18 kg, with focal seizures (including
simple focal, complex focal and secondarily generalised seizures), stable dose of 1 or 2
AEDs during 8-week baseline phase and at least 6 documented focal seizures during 8-
week baseline phase; CT or MRI confirmed absence of progressive brain lesion
Exclusion criteria: treatable cause of seizures (e.g. active infection, neoplasm or metabolic
disorder); diagnosis of generalised epilepsy/generalised seizures; history of generalised
status epilepticus within 2 months before 8-week baseline phase; seizures occurring only
in a cluster pattern; required use of intermittent benzodiazepines > 2 times per month;
evidence or history of clinically significant cardiac, respiratory, hepatic, gastrointestinal,
renal, haematological or progressive neurological disorders; clinically significant ECG
abnormalities; evidence or history ofmalignancy; history of psychiatric ormooddisorders
within the past 6 months requiring medical or electroconvulsive therapy (or both);
diagnosis of schizophrenia or psychotic symptomatology; substance abuse (current or
historical); history of suicide attempt; prior use of rufinamide; and participation in
another clinical trial or use of felbamate within 30 days of 8-week baseline phase
Diagnostic criteria: EEG or CCTV/EEG with features consistent with a diagnosis of
focal seizures
Comorbidities: none.
Comedications: ≤ 2 AEDs.
Total people randomised 313: rufinamide group 156; placebo group 157. All participants
included in analysis. 56 people withdrew from study: rufinamide group 36; placebo
group 20
Interventions Intervention: rufinamide 3200 mg/day.
Control: placebo.
2-phase study: 8-week baseline phase; and 13-week treatment phase (2-week titration
period followed by 11-week maintenance phase)
Outcomes Primary outcomes (as stated in the publication):
1. % change in focal seizures frequency per 28 days during treatment phase relative
to baseline phase.
Secondary outcomes (as stated in the publication):
1. total focal seizure frequency per 28 days during the treatment phase;
2. % responders (50%);
3. % change in secondarily generalised seizures frequency for 28 days during
26Rufinamide add-on therapy for refractory epilepsy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Brodie 2009 (Continued)
treatment phase relative to baseline phase;
4. adverse effects.
Notes Stated aim of study: “This randomized trial was conducted to evaluate efficacy and safety
(seizure control and adverse effects) of rufinamide as adjunctive treatment for refractory
focal seizures.”
Language of publication: English.
Commercial funding: yes.
Publication status (peer review journal): yes.
Publication status (journal supplement): no.
Publication status (abstract): no.
Funded by Eisai Inc.
No conflict of interest.
Aldenkamp 2006 (Epilepsia) is a part of this study (AE/ET1 trial) to evaluate the cognitive
effects of rufinamide
Brodie 2005 (Epilepsia), Rosenfeld 2006 (Epilepsia) and Vazquez 2000 (Epilepsia) are
linked to this study.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated schedule using blocks
of 4.
Allocation concealment (selection bias) Low risk Allocated participants to each of the 2 treat-
ment groups in a 1:1 ratio
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participant and clinical staff blinded.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Investigators blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition rates reported. ITT efficacy anal-
ysis employed.
Selective reporting (reporting bias) Low risk Protocol unavailable but appeared all ex-
pected and prespecified outcomes were re-
ported
Other bias High risk Sponsored by Eisai Inc., the manufacturer
of rufinamide.
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Elger 2010
Methods Randomised, double-blind, placebo-controlled, parallel-group multi-centre study
Number of control centres: not reported.
Country/location: Germany and US.
5 treatment arms: rufinamide 200 mg/day, 400 mg/day, 800 mg/day and 1600 mg/day,
and placebo
Participants Participants: adolescents and adults aged 15-65 years with refractory focal seizures
Gender: 54% males.
Mean age (years): 36.1 (rufinamide all doses group 35.8; placebo group 37.3)
Mean weight (kg): 72.2 (rufinamide all doses group 71.8; placebo group 74.0)
Ethnic groups: not reported.
Median number of focal seizures: rufinamide all doses group 11.4; placebo group 11.7
Duration of epilepsy: not reported.
Inclusion criteria: inpatients or outpatients, aged 15-65 years, who had a diagnosis of
focal seizures, simple or complex (or both), with or without secondary generalisation,
who were receiving stable dosages of 1-3 AEDs for at least 4 weeks prior to starting the
baseline phase and were experiencing≥ 4 seizures per month during the 6 months prior
to the baseline phase
Exclusion criteria: positive pregnancy test, lactation, use of oral/hormonal contraceptives,
history of any seizure type other than focal seizure, status epilepticus within 24 months
prior to study entry, any degenerative neurological disorder or history of a major psychi-
atric disorder within 24 months prior to study entry, or a history of suicide attempts or
ideation; in addition, clinically relevant abnormalities in screening physical examination
or laboratory data; presence of AIDS, acute hepatitis or other clinically relevant medical
disorders; alcohol or drug abuse within 12 months prior to study entry; or the use of
ethosuximide or felbamate
Comorbidities: none.
Comedications: ≤ 3 AEDs.
Total people randomised 647: rufinamide 200 mg/day group 127, rufinamide 400 mg/
day group 125, rufinamide 800 mg/day group 129, rufinamide 1600 mg/day group 133,
and placebo group 133. All participants included in analysis. 93 people withdrew from
study: rufinamide 200 mg/day group 16; rufinamide 400 mg/day group 20; rufinamide
800 mg/day group 19; rufinamide 1600 mg/day group 21; and placebo group 17
Interventions Intervention: rufinamide 200 mg/day, rufinamide 400 mg/day, rufinamide 400 mg/day,
rufinamide 1600 mg/day
Control: placebo.
2-phase study: 12-week baseline phase and 12-week treatment phase
Outcomes Primary outcomes (as stated in the publication):
1. mean % reduction in total focal seizures frequency per 28 days.
Secondary outcomes (as stated in the publication):
1. % responders (50%);
2. adverse effects.
Notes Stated aim of study: “This randomized trial was conducted to evaluate efficacy, safety,
tolerability (seizure control and adverse effects) and pharmacokinetics of rufinamide as
adjunctive treatment for refractory focal seizures.”
Language of publication: English.
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Elger 2010 (Continued)
Commercial funding: yes.
Publication status (peer review journal): yes.
Publication status (journal supplement): no.
Publication status (abstract): no.
Funded by Eisai Inc.
No conflict of interest.
Elger 2005 (Epilepsia), Elger 2006 (Epilepsia) and Stefan 2000 (Epilepsia) are linked to
this study.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation
scheme using block size of 5
Allocation concealment (selection bias) Low risk Allocated participants to each of the 5 treat-
ment groups in a 1:1:1:1:1 ratio
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No details for blinding of participants and
personnel.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Details of outcome assessment blindingnot
provided. Identical medication with differ-
ent dosages
Incomplete outcome data (attrition bias)
All outcomes
Low risk Analysed on ITT basis.
Selective reporting (reporting bias) Low risk Data published in full according to proto-
col.
Other bias High risk Sponsored by Eisai Inc., the manufacturer
of rufinamide.
Glauser 2005
Methods Randomised, double-blind, placebo-controlled, parallel-group multi-centre study
Number of control centres: not reported.
Country/location: not reported.
2 treatment arms: 1 rufinamide, 1 placebo.
Participants Participants: children aged 4-16 years with refractory focal seizures
Gender: not reported.
Mean age: not reported.
Ethnic group: not reported.
Median number of focal seizures: not reported.
Duration of epilepsy: not reported.
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Glauser 2005 (Continued)
Inclusion criteria: children aged 4 to 16 years, with a diagnosis of uncontrolled focal
seizures who were taking stable dosage of 1 or 2 concomitant AEDs
Exclusion criteria: not reported.
Comorbidity: none.
Comedication: ≤ 2 AEDs.
Total people randomised 269. 1 participant excluded from analysis
14 people withdrew from study: rufinamide group 10; placebo group 4
Interventions Intervention: rufinamide 45 mg/kg per day.
Control: placebo.
2-phase study: 56-day baseline/screening phase, and 91-day treatment phase (14-day
titration phase followed by 77-day maintenance phase)
Outcomes Primary outcomes (as stated in the publication):
1. mean % reduction in total focal seizures frequency per 28 days during treatment
phase relative to baseline.
Secondary outcomes (as stated in the publication):
1. total focal seizure frequency per 28 days;
2. % responders (50%);
3. adverse effects.
Notes Stated aim of study: “This study aimed to assess the efficacy and safety (seizure control
and adverse effects) of rufinamide as adjunctive therapy in paediatric patients with in-
adequately controlled primary focal seizures.”
Language of publication: English.
Commercial funding: yes.
Publication status (peer review journal): no.
Publication status (journal supplement): no.
Publication status (abstract): yes.
Supported by Eisai Inc.
No conflict of interest.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details of randomisation provided.
Allocation concealment (selection bias) Unclear risk No information provided.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Insufficient information available to make
judgement.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information available to make
judgement.
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Glauser 2005 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No reasons reported for exclusion of 1 par-
ticipant from analysis
Selective reporting (reporting bias) Low risk Appeared all expected and prespecified out-
comes were reported
Other bias High risk Sponsored by Eisai Inc., the manufacturer
of rufinamide.
Glauser 2008
Methods Randomised, double-blind, placebo-controlled, parallel-group multi-centre study
Number of control centres: 36.
Country/location: Belgium, Brazil, Germany, Hungary, Italy, Norway, Poland, Spain
and US
2 treatment arms: 1 rufinamide, 1 placebo.
Participants Participants: aged 4-30 years with Lennox-Gastaut syndrome.
Gender: 62.3% males (rufinamide group 62.2%; placebo group 62.5%)
Median age (years): 12.0 (rufinamide group 13.0; placebo group 10.5%)
Median weight (kg): 34.7 (rufinamide group 35.9; placebo group 33.5)
Ethnic groups: white 83.3%, black 7.2%, other 9.5%.
Median number of seizures: rufinamide group 290; placebo group 205
Duration of epilepsy (years): 7.7 (rufinamide group 7.9; placebo group 7.5)
Inclusion criteria: aged 4-30 years with established Lennox-Gastaut syndrome;minimum
of 90 seizures inmonth before the 28-day baseline period; EEGwithin 6months of study
entry demonstrating a pattern of slow spike-and-wave complexes (< 2.5 Hz); weight ≥
18 kg; fixed-dose regimen of 1-3 concomitant AEDs during the baseline period; and CT
scan or MRI study confirming absence of a progressive lesion
Exclusion criteria:≥ 3 AEDs; pregnant or not using adequate contraception; correctable
aetiology of their seizures (active infection, neoplasm, metabolic disturbance); history of
generalised tonic-clonic status epilepticus within 30 days before baseline; history of any
clinically significant non-neurological medical condition
Diagnostic criteria: Lennox-Gastaut syndrome was diagnosed based on a history of tonic
or atonic (or both) seizures and atypical absence seizures and slow spike-and-wave com-
plex patterns on EEG within 6 months before the baseline period
Comorbidities: none.
Comedications: ≤ 2 AEDs.
Total people randomised 139 (1 patient was excluded from analysis): rufinamide group
74; placebo group 64. 15 people withdrew from the study: rufinamide group 10; placebo
group 5
Interventions Intervention: rufinamide 45 mg/kg (dose by bodyweight: 1000 mg, 1800 mg, 2400 mg
and 3200 mg) per day
Control: placebo.
2-phase study: 28-day pre-randomisation baseline phase and 84-day treatment phase
(14-day titration phase followed by 70-day maintenance phase)
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Glauser 2008 (Continued)
Outcomes Primary outcomes (as stated in the publication):
1. median % reduction in total seizures frequency per 28 days during treatment
phase relative to baseline;
2. median percentage reduction in tonic-atonic seizures frequency per 28 days
during treatment phase relative to baseline;
3. seizure severity rating from the global evaluation of the participant’s condition.
Secondary outcomes (as stated in the publication):
1. % responders (50%);
2. adverse effects.
Notes Stated aim of study: “This randomized trial was conducted to evaluate efficacy and
tolerability (seizure control and adverse effects) of rufinamide adjunctive therapy in
patients with Lennox-Gastaut syndrome.”
Language of publication: English.
Commercial funding: yes.
Publication status (peer review journal): yes.
Publication status (journal supplement): no.
Publication status (abstract): no.
Sponsored by Eisai Pharmaceutical and conducted by Novartis Pharmaceutical
No conflict of interest.
Glauser 2005 (Annals of Neurology), Glauser 2005 (Neurology), Glauser 2007 (Epilepsia)
, Glauser 2009 (Epilepsia), Kluger 2006 (Epilepsia), Krauss 2007 (Epilepsia), McMurray
2016 (Neurology & Therapy), Striano 2015 (Epilepsia) are linked to this study.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants randomised in blocks of 4
to receive either rufinamide or matching
placebo
Allocation concealment (selection bias) Low risk Assigned sequential numbers at each site
during the first visit
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical tablets and packaging.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Details of outcome assessment blindingnot
provided.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition rates reported. ITT efficacy anal-
ysis employed.
Selective reporting (reporting bias) Low risk Protocol unavailable but appeared all ex-
pected and prespecified outcomes were re-
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Glauser 2008 (Continued)
ported
Other bias High risk Sponsored by Eisai Inc., the manufacturer
of rufinamide.
Ohtsuka 2014
Methods Randomised, double-blind, placebo-controlled, multi-centre study in Japan
Number of control centres: not reported.
Country/location: Japan.
2 treatment arms: 1 rufinamide, 1 placebo.
Participants Participants: people aged 4-30 years with Lennox-Gastaut syndrome
Gender: 62% males (rufinamide group 60.7%; placebo group 63.3%)
Mean age (years): 15 (rufinamide group 16.0; placebo group 13.9)
Mean weight (kg): 34.7 (rufinamide group 39.0; placebo group 40.9)
Ethnic groups: not reported.
Median number of seizures: rufinamide group 253; placebo group 296.7
Duration of epilepsy (years): 9.9 (rufinamide group 10.5; placebo group 9.3 years)
Inclusion criteria: aged 4-30 years, weighing ≥ 15 kg with established Lennox-Gastaut
syndrome
Exclusion criteria: people with experienced tonic-clonic status epilepticus during baseline
period; if they had other clinically severe diseases or ECG/laboratory abnormalities
Diagnostic criteria: Lennox-Gastaut syndrome diagnosed based on history of tonic or
atonic (or both) seizures and atypical absence seizures and slow spike-and-wave complex
patterns on EEG within 6 months before the baseline period
Comorbidities: none.
Comedications: ≤ 3 AEDs.
Total people randomised 59: rufinamide group 29; placebo group 30. 1 participant
assigned to rufinamide group excluded from analysis. 5 people withdrew from study:
rufinamide group 4; placebo group 1
Interventions Intervention: rufinamide 45 mg/kg (dose by bodyweight: 1000 mg, 1800 mg, 2400 mg
or 3200 mg) per day
Control: placebo.
2-phase study: 4-week baseline phase and 12-week treatment phase (2-week titration
phase followed by 10-weekmaintenance phase). In addition, a 4th phase: either a follow-
up visit or entry into an open-label extension
Outcomes Primary outcomes (as stated in the publication):
1. % change in focal seizures frequency per 28 days during treatment phase relative
to baseline phase.
Secondary outcomes (as stated in the publication):
1. % change in total focal seizure frequency per 28 days during the treatment phase;
2. % responders (50%);
3. % change in the frequency of seizures other than tonic atonic seizures for 28 days
during treatment phase;
4. adverse effects.
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Ohtsuka 2014 (Continued)
Notes Stated aim of study: “This randomized trial in Japan was conducted to evaluate efficacy
and tolerability (seizure control and adverse effects) and pharmacokinetics of rufinamide
as an adjunctive therapy in patients with Lennox-Gastaut syndrome.”
Language of publication: English.
Commercial funding: yes.
Publication status (peer review journal): yes.
Publication status (journal supplement): no.
Publication status (abstract): no.
Sponsored by Eisai Pharmaceutical.
No conflict of interest.
Study design referred to previous trial of rufinamide for Lennox-Gastaut syndrome
(Glauser 2008).
NCT01140951 and Ohtsuka 2016 (Epilepsy Research) were linked to this study.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation schedule that assigned each
participant to rufinamide group or placebo
group in a 1:1 ratio
Allocation concealment (selection bias) Low risk Participants randomised to receive rufi-
namide or placebo in a 1:1 ratio according
to bodyweight
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participant and clinical staff blinded.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Investigators blinded. Identical tablets and
packaging.
Incomplete outcome data (attrition bias)
All outcomes
Low risk All evaluated on ITT bias.
Selective reporting (reporting bias) Low risk Appeared all expected and prespecified out-
comes were reported
Other bias High risk Sponsored by Eisai Inc., the manufacturer
of rufinamide.
AED: antiepileptic drug; CCTV: closed-circuit television; CT: computer tomography; ECG: electrocardiograph; EEG: electroen-
cephalogram; ITT: intention to treat; MRI: magnetic resonance imaging.
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Benedict 2010 Not an RCT.
Biton 2005 Ineligible population (people with primary generalised tonic-clonic)
Critchley 2005 Ineligible population (healthy people).
Kim 2012 Not an RCT.
Kluger 2007 Not an RCT.
Knupp 2016 Not an RCT.
Lesser 2005 No rufinamide in add-on.
Madeddu 2013 Ineligible population (people with epileptic encephalopathies secondary to complex brain malformations)
Palhagen 2001 Ineligible population (participants with no refractory epilepsy)
Racine 2000 Conference (4th European Congress on Epileptology): abstract and full paper not available
Todorov 2005 No rufinamide in add-on.
Xu 2016 Ineligible population (healthy people).
RCT: randomised controlled trial;
Characteristics of ongoing studies [ordered by study ID]
Arzimanoglou 2016
Trial name or title Safety and Pharmacokinetic Profile of Rufinamide in Pediatric Patients Aged Less than 4 Years with Lennox-
Gastaut Syndrome: an Interim Analysis from a Multicenter, Randomized, Active-Controlled, Open-Label
Study
Methods Randomised, active-controlled, open-label multi-centre study
Number of control centres: 20.
Country/location: North America and the EU.
2 treatment arms: 1 rufinamide, 1 any other approved AED.
Participants Participants: children aged 1 to < 4 years.
Gender: 63.9% boys; 36.1% girls.
Mean age (months): 29.2 (rufinamide group 28.3; any other AED group 31.3)
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Arzimanoglou 2016 (Continued)
Inclusion criteria: aged 1 to < 4 years; clinical diagnosis of LGS, which might include the presence of multiple
types of seizures progressively enriching the clinical picture, a slow background EEG rhythm, slow spike-wave
pattern (< 3 Hz) or the presence of polyspikes, or both
Exclusion criteria: diagnosedwith benignmyoclonic epilepsy of infancy, atypical benign focal epilepsy (pseudo-
Lennox syndrome), or continuous spike-waves of slow sleep, as well as other epilepsy syndromes not suggesting
the electroclinical profile of children within the LGS spectrum; additionally, children with familial short QT
syndrome and with prior treatment with rufinamide
Comedications: ≤ 3 AEDs.
Total children randomised 37: rufinamide group 25; any other approved AED group 12. 1 child assigned to
any other AED group was excluded from analysis
Interventions Intervention: rufinamide up to 45 mg/kg per day.
Control: any other AED.
2-phase study: 8-week pre-randomisation phase included a screening period and baseline visit, and a 106-
week randomisation phase included titration and maintenance. Interim analysis at 6 months
Outcomes Primary outcomes:
1. overall safety and tolerability (all adverse events);
2. age group-specific pharmacokinetics of rufinamide using a population approach;
3. cognitive and behavioural effects.
Starting date June 2011.
Contact information aarzimanoglou@orange.fr (A. Arzimanoglou).
Notes Funded by Eisai Inc.
AED: antiepileptic drug; EEG: electroencephalogram; LGS: Lennox-Gastaut syndrome.
36Rufinamide add-on therapy for refractory epilepsy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
D A T A A N D A N A L Y S E S
Comparison 1. Rufinamide versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 ≥ 50% reduction in seizure
frequency
6 1759 Risk Ratio (M-H, Fixed, 95% CI) 1.79 [1.44, 2.22]
2 Seizure freedom 1 73 Risk Ratio (M-H, Fixed, 95% CI) 1.32 [0.36, 4.86]
3 Treatment withdrawal 6 1759 Risk Ratio (M-H, Fixed, 95% CI) 1.83 [1.45, 2.31]
4 Adverse effects 6 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 Dizziness 3 1295 Risk Ratio (M-H, Fixed, 95% CI) 2.52 [1.90, 3.34]
4.2 Fatigue 3 1295 Risk Ratio (M-H, Fixed, 95% CI) 1.46 [1.08, 1.97]
4.3 Headache 3 1228 Risk Ratio (M-H, Fixed, 95% CI) 1.36 [1.08, 1.69]
4.4 Somnolence 6 1759 Risk Ratio (M-H, Fixed, 95% CI) 1.94 [1.44, 2.61]
4.5 Nausea 3 1295 Risk Ratio (M-H, Fixed, 95% CI) 1.87 [1.33, 2.64]
4.6 Vomiting 4 777 Risk Ratio (M-H, Fixed, 95% CI) 2.95 [1.80, 4.82]
4.7 Diplopia 3 1295 Risk Ratio (M-H, Fixed, 95% CI) 4.60 [2.53, 8.38]
Analysis 1.1. Comparison 1 Rufinamide versus placebo, Outcome 1 ≥ 50% reduction in seizure frequency.
Review: Rufinamide add-on therapy for refractory epilepsy
Comparison: 1 Rufinamide versus placebo
Outcome: 1≥ 50% reduction in seizure frequency
Study or subgroup Rufinamide Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Biton 2011 52/160 25/175 22.6 % 2.28 [ 1.49, 3.48 ]
Brodie 2009 44/156 29/157 27.4 % 1.53 [ 1.01, 2.31 ]
Elger 2010 60/514 12/133 18.1 % 1.29 [ 0.72, 2.33 ]
Glauser 2005 37/135 24/133 22.9 % 1.52 [ 0.96, 2.39 ]
Glauser 2008 23/74 7/64 7.1 % 2.84 [ 1.31, 6.18 ]
Ohtsuka 2014 7/28 2/30 1.8 % 3.75 [ 0.85, 16.55 ]
Total (95% CI) 1067 692 100.0 % 1.79 [ 1.44, 2.22 ]
Total events: 223 (Rufinamide), 99 (Placebo)
Heterogeneity: Chi2 = 5.76, df = 5 (P = 0.33); I2 =13%
Test for overall effect: Z = 5.26 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours placebo Favours rufinamide
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Analysis 1.2. Comparison 1 Rufinamide versus placebo, Outcome 2 Seizure freedom.
Review: Rufinamide add-on therapy for refractory epilepsy
Comparison: 1 Rufinamide versus placebo
Outcome: 2 Seizure freedom
Study or subgroup Rufinamide Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Brodie 2009 6/44 3/29 100.0 % 1.32 [ 0.36, 4.86 ]
Total (95% CI) 44 29 100.0 % 1.32 [ 0.36, 4.86 ]
Total events: 6 (Rufinamide), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.42 (P = 0.68)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours placebo Favours rufinamide
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Analysis 1.3. Comparison 1 Rufinamide versus placebo, Outcome 3 Treatment withdrawal.
Review: Rufinamide add-on therapy for refractory epilepsy
Comparison: 1 Rufinamide versus placebo
Outcome: 3 Treatment withdrawal
Study or subgroup Rufinamide Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Biton 2011 64/160 36/175 37.4 % 1.94 [ 1.37, 2.75 ]
Brodie 2009 23/156 6/157 6.5 % 3.86 [ 1.62, 9.22 ]
Elger 2010 137/514 26/133 44.9 % 1.36 [ 0.94, 1.98 ]
Glauser 2005 10/135 4/133 4.4 % 2.46 [ 0.79, 7.66 ]
Glauser 2008 10/74 5/64 5.8 % 1.73 [ 0.62, 4.80 ]
Ohtsuka 2014 3/28 1/30 1.0 % 3.21 [ 0.35, 29.12 ]
Total (95% CI) 1067 692 100.0 % 1.83 [ 1.45, 2.31 ]
Total events: 247 (Rufinamide), 78 (Placebo)
Heterogeneity: Chi2 = 5.85, df = 5 (P = 0.32); I2 =15%
Test for overall effect: Z = 5.14 (P < 0.00001)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours rufinamide Favours placebo
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Analysis 1.4. Comparison 1 Rufinamide versus placebo, Outcome 4 Adverse effects.
Review: Rufinamide add-on therapy for refractory epilepsy
Comparison: 1 Rufinamide versus placebo
Outcome: 4 Adverse effects
Study or subgroup Rufinamide Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Dizziness
Biton 2011 47/160 15/175 25.2 % 3.43 [ 2.00, 5.88 ]
Brodie 2009 66/156 22/157 38.5 % 3.02 [ 1.97, 4.63 ]
Elger 2010 68/514 13/133 36.3 % 1.35 [ 0.77, 2.37 ]
Subtotal (95% CI) 830 465 100.0 % 2.52 [ 1.90, 3.34 ]
Total events: 181 (Rufinamide), 50 (Placebo)
Heterogeneity: Chi2 = 6.63, df = 2 (P = 0.04); I2 =70%
Test for overall effect: Z = 6.39 (P < 0.00001)
2 Fatigue
Biton 2011 27/160 18/175 27.1 % 1.64 [ 0.94, 2.86 ]
Brodie 2009 25/156 13/157 20.4 % 1.94 [ 1.03, 3.64 ]
Elger 2010 96/514 21/133 52.5 % 1.18 [ 0.77, 1.82 ]
Subtotal (95% CI) 830 465 100.0 % 1.46 [ 1.08, 1.97 ]
Total events: 148 (Rufinamide), 52 (Placebo)
Heterogeneity: Chi2 = 1.84, df = 2 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 2.48 (P = 0.013)
3 Headache
Brodie 2009 59/156 38/157 37.2 % 1.56 [ 1.11, 2.20 ]
Elger 2010 129/514 32/133 49.9 % 1.04 [ 0.74, 1.46 ]
Glauser 2005 26/135 13/133 12.9 % 1.97 [ 1.06, 3.67 ]
Subtotal (95% CI) 805 423 100.0 % 1.36 [ 1.08, 1.69 ]
Total events: 214 (Rufinamide), 83 (Placebo)
Heterogeneity: Chi2 = 4.38, df = 2 (P = 0.11); I2 =54%
Test for overall effect: Z = 2.67 (P = 0.0075)
4 Somnolence
Biton 2011 22/160 13/175 20.7 % 1.85 [ 0.97, 3.55 ]
Brodie 2009 32/156 19/157 31.6 % 1.70 [ 1.01, 2.86 ]
Elger 2010 47/514 5/133 13.3 % 2.43 [ 0.99, 5.99 ]
Glauser 2005 20/135 11/133 18.5 % 1.79 [ 0.89, 3.59 ]
Glauser 2008 18/74 8/64 14.3 % 1.95 [ 0.91, 4.17 ]
0.002 0.1 1 10 500
Favours rufinamide Favours placebo
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(. . . Continued)
Study or subgroup Rufinamide Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ohtsuka 2014 5/28 1/30 1.6 % 5.36 [ 0.67, 43.07 ]
Subtotal (95% CI) 1067 692 100.0 % 1.94 [ 1.44, 2.61 ]
Total events: 144 (Rufinamide), 57 (Placebo)
Heterogeneity: Chi2 = 1.48, df = 5 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 4.33 (P = 0.000015)
5 Nausea
Biton 2011 23/160 9/175 19.5 % 2.80 [ 1.33, 5.86 ]
Brodie 2009 41/156 18/157 40.8 % 2.29 [ 1.38, 3.81 ]
Elger 2010 42/514 11/133 39.7 % 0.99 [ 0.52, 1.87 ]
Subtotal (95% CI) 830 465 100.0 % 1.87 [ 1.33, 2.64 ]
Total events: 106 (Rufinamide), 38 (Placebo)
Heterogeneity: Chi2 = 5.62, df = 2 (P = 0.06); I2 =64%
Test for overall effect: Z = 3.59 (P = 0.00033)
6 Vomiting
Brodie 2009 21/156 7/157 35.2 % 3.02 [ 1.32, 6.90 ]
Glauser 2005 18/135 8/133 40.7 % 2.22 [ 1.00, 4.92 ]
Glauser 2008 16/74 4/64 21.7 % 3.46 [ 1.22, 9.82 ]
Ohtsuka 2014 4/28 0/30 2.4 % 9.62 [ 0.54, 170.96 ]
Subtotal (95% CI) 393 384 100.0 % 2.95 [ 1.80, 4.82 ]
Total events: 59 (Rufinamide), 19 (Placebo)
Heterogeneity: Chi2 = 1.23, df = 3 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 4.31 (P = 0.000016)
7 Diplopia
Biton 2011 14/160 2/175 14.4 % 7.66 [ 1.77, 33.17 ]
Brodie 2009 31/156 5/157 37.6 % 6.24 [ 2.49, 15.63 ]
Elger 2010 37/514 4/133 48.0 % 2.39 [ 0.87, 6.60 ]
Subtotal (95% CI) 830 465 100.0 % 4.60 [ 2.53, 8.38 ]
Total events: 82 (Rufinamide), 11 (Placebo)
Heterogeneity: Chi2 = 2.48, df = 2 (P = 0.29); I2 =19%
Test for overall effect: Z = 4.99 (P < 0.00001)
0.002 0.1 1 10 500
Favours rufinamide Favours placebo
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A P P E N D I C E S
Appendix 1. Epilepsy Specialized Register search strategy
rufinamide OR banzel OR “cgp 33101” OR “e 2080” OR inovelon OR “ruf 331” OR xilep AND INREGISTER
Appendix 2. CENTRAL via CRSO search strategy
#1 (“banzel” OR “cgp 33101” OR “e 2080” OR inovelon OR “ruf 331” OR rufinamide OR “xilep”):TI,AB,KY
#2 * NOT INMEDLINE
#3 #1 AND #2
Appendix 3. MEDLINE search strategy
This strategy is based on the Cochrane Highly Sensitive Search Strategy for identifying randomized trials (Lefebvre 2011).
1. rufinamide.mp.
2. exp Epilepsy/
3. exp Seizures/
4. (epilep$ or seizure$ or convuls$).tw.
5. 2 or 3 or 4
6. exp *Pre-Eclampsia/ or exp *Eclampsia/
7. 5 not 6
8. (randomized controlled trial or controlled clinical trial or pragmatic clinical trial).pt. or (randomi?ed or placebo or randomly).ab.
9. clinical trials as topic.sh.
10. trial.ti.
11. 8 or 9 or 10
12. exp animals/ not humans.sh.
13. 11 not 12
14. 1 and 7 and 13
15. remove duplicates from 14
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I N D E X T E R M S
Medical Subject Headings (MeSH)
Anticonvulsants [adverse effects; ∗therapeutic use]; Drug Resistant Epilepsy [∗drug therapy]; Drug Therapy, Combination; Triazoles
[adverse effects; ∗therapeutic use]
MeSH check words
Adolescent; Adult; Aged; Aged, 80 and over; Child; Child, Preschool; Female; Humans; Male; Middle Aged
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